| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TP53RK |
| Uniprot No | Q96S44 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-253 aa |
| 活性数据 | MAAARATTPA DGEEPAPEAE ALAAARERSS RFLSGLELVK QGAEARVFRG RFQGRAAVIK HRFPKGYRHP ALEARLGRRR TVQEARALLR CRRAGISAPV VFFVDYASNC LYMEEIEGSV TVRDYIQSTM ETEKTPQGLS NLAKTIGQVL ARMHDEDLIH GDLTTSNMLL KPPLEQLNIV LIDFGLSFIS ALPEDKGVDL YVLEKAFLST HPNTETVFEA FLKSYSTSSK KARPVLKKLD EVRLRGRKRS MVG |
| 分子量 | 28.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人TP53RK蛋白的参考文献示例，基于相关领域的典型研究方向整理，供参考：
---
1. **文献名称**：*Functional Characterization of Recombinant Human TP53RK Kinase in p53-Mediated DNA Repair*
**作者**：Liu Y, et al.
**摘要**：研究通过大肠杆菌表达系统制备重组人TP53RK蛋白，证实其能够磷酸化p53蛋白的第15位丝氨酸，增强p53在DNA损伤修复中的转录活性，为TP53RK在肿瘤抑制中的作用提供实验依据。
2. **文献名称**：*Structural Basis of TP53RK Kinase Activity Revealed by Cryo-EM Analysis*
**作者**：Wang X, et al.
**摘要**：利用冷冻电镜解析了重组TP53RK蛋白的三维结构，揭示其激酶活性域的构象变化及底物结合位点，为靶向药物设计提供结构基础。
3. **文献名称**：*Development of a Recombinant TP53RK-Based High-Throughput Screening Assay for Anticancer Drug Discovery*
**作者**：Kim H, et al.
**摘要**：建立基于重组TP53RK蛋白的高通量激酶抑制实验平台，筛选出多个潜在小分子抑制剂，验证其对癌细胞增殖的抑制作用。
4. **文献名称**：*TP53RK Regulates the KEOPS Complex and tRNA Modification via Recombinant Interaction Studies*
**作者**：Martinez S, et al.
**摘要**：通过重组蛋白互作实验证明TP53RK是KEOPS复合体的核心成员，参与tRNA修饰及基因组稳定性调控，提示其功能不限于p53通路。
---
**注意事项**：
- 上述文献为假设性示例，实际研究中TP53RK可能与KEOPS复合体(如Bud32同源蛋白)或其他通路相关。建议通过数据库(如PubMed、Google Scholar)以“TP53RK recombinant”“KEOPS complex”“p53 kinase”等关键词检索最新文献。
- TP53RK的别名可能包括“BUD32”或“PRPK”，需根据具体研究背景调整检索策略。
The tumor protein p53-regulated kinase (TP53RK), also known as P53RKA or PRPK, is a serine/threonine kinase encoded by the TP53RK gene. It belongs to the CAMK (calcium/calmodulin-dependent protein kinase) family and plays a critical role in cellular stress responses, DNA damage repair, and cell cycle regulation. TP53RK is functionally linked to the p53 tumor suppressor pathway, acting both as a downstream effector and an upstream regulator. It phosphorylates p53 at specific residues, stabilizing and enhancing its transcriptional activity, which promotes apoptosis or cell cycle arrest in response to genomic instability. Conversely, TP53RK expression is itself upregulated by p53. forming a positive feedback loop to amplify stress signals.
Dysregulation of TP53RK has been implicated in cancer development. Reduced TP53RK expression is observed in various malignancies, correlating with tumor progression and poor prognosis. Its inactivation may impair p53-mediated tumor suppression, facilitating uncontrolled cell proliferation. Recombinant human TP53RK protein, produced via expression systems like E. coli or mammalian cells, is widely used to study its biochemical properties, kinase activity, and interactions with p53 or other partners. Purification typically involves affinity tags (e.g., His-tag) followed by chromatography. Current research explores TP53RK’s potential as a therapeutic target or biomarker, particularly in cancers with p53 pathway defects. Notably, it has been investigated in combination therapies to reactivate wild-type p53 function or sensitize cells to chemotherapy. Clinical relevance remains under active investigation, with ongoing studies evaluating its role in personalized oncology approaches.
×
